Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT06303167
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Guangzhou Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT06304441
- Locations
- 🇨🇳
The Third People's Hospital of Huizhou (Huizhou Hospital of Guangzhou Medical University), Huizhou, Guangdong, China
Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jair Bar, M.D., Ph.D.
- Target Recruit Count
- 20
- Registration Number
- NCT06206850
- Locations
- 🇮🇱
Sheba Medical Center, Jusidman Cancer Center, Ramat Gan, Israel
🇮🇱Sheba Medical Center, Ramat-gan, Israel
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT06194448
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06142617
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Peking, China
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06093503
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Jonathan Riess
- Target Recruit Count
- 36
- Registration Number
- NCT06067776
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 4
- Registration Number
- NCT06032936
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 44
- Registration Number
- NCT06018688
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT06014827
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.